Loading...
•
Mar 31, 2024
Corcept Therapeutics Q1 2024 Earnings Report
Reported a revenue increase of 39% compared to the same period in 2023, with a net income per share of $0.25 (diluted).
Key Takeaways
Corcept Therapeutics announced first quarter financial results with revenue of $146.8 million, a 39% increase over the same period in 2023. The company increased its 2024 revenue guidance to $620 - $650 million.
Revenue of $146.8 million, a 39 percent increase over the same period in 2023
Increased 2024 revenue guidance to $620 – $650 million, from $600 – $630 million
Net income per common share of $0.25 (diluted), compared to $0.14 in first quarter 2023
Cash and investments of $451.0 million as of March 31, 2024
Corcept Therapeutics
Corcept Therapeutics
Corcept Therapeutics Revenue by Segment
Revenue by Segment
Product Revenue, Net Revenue
CapyFin.com Forward Guidance
The company increased its 2024 revenue guidance to $620 – $650 million.